IMR Press / EJGO / Volume 42 / Issue 6 / DOI: 10.31083/j.ejgo4206171
Open Access Original Research
Prognostic value of Ephrin A receptors in 3554 breast cancer patients: microarray data with 20 years of follow-up
Xi Zhang1,*,†Xin Mu2,†Ou Huang3Jialin Chen1Debo Chen1,*
Show Less
1 Department of Breast Oncology, The First Hospital of Quanzhou Affiliated to Fujian Medical University, 362000 Quanzhou, Fujian, China
2 Department of Urology, The Second Affiliated Hospital of Fujian Medical University, 362000 Quanzhou, Fujian, China
3 Comprehensive Breast Health Center, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, 200025 Shanghai, China

These authors contributed equally.

Eur. J. Gynaecol. Oncol. 2021, 42(6), 1172–1179; https://doi.org/10.31083/j.ejgo4206171
Submitted: 21 February 2021 | Revised: 1 April 2021 | Accepted: 19 April 2021 | Published: 15 December 2021
Copyright: © 2021 The Author(s). Published by IMR Press.
This is an open access article under the CC BY 4.0 license (https://creativecommons.org/licenses/by/4.0/).
Abstract

Objective: Ephrin A (EphA) receptors are involved in tumorigenesis, metastasis, and angiogenesis, making them attractive candidates for new anti-cancer therapies. Here, we investigated the prognostic value of EphA receptor expression in breast cancer (BC). Methods: We analyzed EphA mRNA levels and survival information through the “Kaplan-Meier plotter” database. In total, we included 3554 breast cancer patients with a median follow-up of 20 years. A 95% confidence interval (CI) and Hazard ratio (HR) were used to assess the overall relative risk of BC outcome. Results: Our results showed that EphA1 (HR = 0.67, 95% CI: 0.6–0.75, p = 6.3 × 10-12), EphA2 (HR = 0.79, 95% CI: 0.7–0.89, p = 5.2 × 10-5), EphA3 (HR = 0.78, 95% CI: 0.69–0.87, p = 1.7 × 10-5), EphA4 (HR = 0.72, 95% CI: 0.61–0.86, p = 3 × 10-4), EphA5 (HR = 0.68, 95% CI: 0.57–0.82, p = 4.3 × 10-5), EphA6 (HR = 0.8, 95% CI: 0.66–0.98, p = 0.027), EphA8 (HR = 0.52, 95% CI: 0.44–0.62, p = 2.6 × 10-14) and EphA10 (HR = 0.58, 95% CI: 0.5–0.68, p = 3.6 × 10-11) were correlated with better relapse-free survival (RFS), while EphA7 (HR = 1.19, 95% CI: 1.02–1.4, p = 0.031) was correlated with a worse RFS in breast cancer patients. Conclusions: Our analyisis demonstrate that profiling EphA receptor mRNA expression in BC patients has prognostic value.

Keywords
Breast cancer
Ephrin A receptors
Prognosis
Kaplan-Meier plotter
Hazard ratio (HR)
Figures
Fig. 1.
Share
Back to top